Catalyst Private Wealth LLC Buys 121 Shares of Johnson & Johnson (NYSE:JNJ)

Catalyst Private Wealth LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.3% in the 4th quarter, Holdings Channel reports. The firm owned 2,045 shares of the company’s stock after acquiring an additional 121 shares during the quarter. Catalyst Private Wealth LLC’s holdings in Johnson & Johnson were worth $296,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of JNJ. Marion Wealth Management raised its stake in Johnson & Johnson by 11.4% during the fourth quarter. Marion Wealth Management now owns 1,626 shares of the company’s stock worth $235,000 after buying an additional 167 shares during the last quarter. Parisi Gray Wealth Management grew its holdings in Johnson & Johnson by 4.0% during the 4th quarter. Parisi Gray Wealth Management now owns 9,829 shares of the company’s stock worth $1,422,000 after acquiring an additional 381 shares during the period. Miracle Mile Advisors LLC grew its holdings in Johnson & Johnson by 86.3% during the 4th quarter. Miracle Mile Advisors LLC now owns 119,200 shares of the company’s stock worth $17,239,000 after acquiring an additional 55,200 shares during the period. Horizon Wealth Management LLC boosted its position in shares of Johnson & Johnson by 13.8% during the 4th quarter. Horizon Wealth Management LLC now owns 1,683 shares of the company’s stock valued at $243,000 after purchasing an additional 204 shares in the last quarter. Finally, Sunflower Bank N.A. grew its stake in Johnson & Johnson by 2.4% during the fourth quarter. Sunflower Bank N.A. now owns 10,572 shares of the company’s stock worth $1,529,000 after purchasing an additional 244 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on JNJ shares. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 7th. Guggenheim raised their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Royal Bank of Canada upped their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $174.71.

Johnson & Johnson Stock Up 1.7 %

Shares of NYSE:JNJ opened at $144.50 on Tuesday. The business’s 50 day moving average is $149.39 and its 200 day moving average is $156.10. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The stock has a market cap of $347.90 billion, a price-to-earnings ratio of 20.91, a PEG ratio of 2.52 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. During the same period in the previous year, the firm earned $2.66 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, sell-side analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 71.78%.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.